共 85 条
Genetic evidence for an additional factor required for erythropoietin-induced signal transduction
被引:20
作者:
Gaffen, SL
Lai, SY
Longmore, GD
Liu, KD
Goldsmith, MA
机构:
[1] Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA
[2] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
[3] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA
来源:
关键词:
D O I:
10.1182/blood.V94.1.74.413k36_74_86
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Erythropoietin (EPO) and its receptor (EPOR) are required for the development of mature erythrocytes. After binding of ligand, the EPOR activates a variety of signaling pathways that ultimately control cellular proliferation, survival, and specific gene expression. Although erythroid progenitors appear to be the principal EPO-responsive cell type in vivo due to the restricted expression of the EPOR, many growth factor-dependent cell lines expressing the EPOR can respond to EPO by activating many or all of these pathways. In the present study, we have identified a cellular context (the interleukin-2 [IL-2]-dependent HT-2 line) in which the EPO stimulation of the EPOR fails to support cellular proliferation, STAT-5 induction, or MAPK activation, despite efficient phosphorylation of the EPOR and JAK2 and inhibition of apoptosis after withdrawal of IL-2. Interestingly, when we fused HT-2 cells expressing the EPOR with Ba/F3 cells in a complementation assay, the resulting hybridomas proliferated and potently activated STAT-5 and MAPK in response to EPO. These data indicate that an unidentified cellular factor is needed to mediate signaling by the EPOR. Moreover, Ba/F3 cells apparently express this factor(s) and somatic fusions can, therefore, confer EPO responsiveness to HT-2 cells that lack this factor. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:74 / 86
页数:13
相关论文